Search research articles
Contact Us
Filters
Showing results (81-90 of 109) with videos related to
Page
of 11
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 9, 2020
Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
Marie Øbro Fosbøl, Sorel Kurbegovic, Helle Hjorth Johannesen, et al.
Archives of General Psychiatry
|
June 8, 2011
In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users
David Erritzoe, Vibe G Frokjaer, Klaus K Holst, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
February 22, 2008
Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients
David Erritzoe, Hans Rasmussen, Klaus T Kristiansen, et al.
Frontiers in Nuclear Medicine
|
October 2, 2024
Optimization and Evaluation of Al<sup>18</sup>F Labeling Using a NOTA-or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR
Troels E Jeppesen, Marina Simón, Josephine Torp, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
January 1, 2010
Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding
Vibe G Frokjaer, Maj Vinberg, David Erritzoe, et al.
Science (New York, N.Y.)
|
December 4, 2025
Hexatic phase in covalent two-dimensional silver iodide
Thuy An Bui, David Lamprecht, Jacob Madsen, et al.
Diagnostics (Basel, Switzerland)
|
April 23, 2022
First-in-Human Study of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET for Integrin α<sub>v</sub>β<sub>3</sub> Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability
Malene Martini Clausen, Esben Andreas Carlsen, Camilla Christensen, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
June 27, 2012
Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response
Vibe Gedsoe Frokjaer, David Erritzoe, Klaus Kähler Holst, et al.
Nuclear Medicine and Biology
|
November 21, 2012
Radiolabelling and PET brain imaging of the α₁-adrenoceptor antagonist Lu AE43936
Rune Risgaard, Anders Ettrup, Thomas Balle, et al.
Scientific Reports
|
October 31, 2024
Phase II study of uPAR-PET/CT for staging of primary breast cancer in comparison with ultrasound and fine needle biopsies
Marie Øbro Fosbøl, Esben Andreas Carlsen, Malene Brandt-Larsen, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 109) with videos related to
Sort By:
Page
of 11
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 9, 2020
Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
Marie Øbro Fosbøl, Sorel Kurbegovic, Helle Hjorth Johannesen, et al.
Archives of General Psychiatry
|
June 8, 2011
In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users
David Erritzoe, Vibe G Frokjaer, Klaus K Holst, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
February 22, 2008
Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients
David Erritzoe, Hans Rasmussen, Klaus T Kristiansen, et al.
Frontiers in Nuclear Medicine
|
October 2, 2024
Optimization and Evaluation of Al<sup>18</sup>F Labeling Using a NOTA-or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR
Troels E Jeppesen, Marina Simón, Josephine Torp, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
January 1, 2010
Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding
Vibe G Frokjaer, Maj Vinberg, David Erritzoe, et al.
Science (New York, N.Y.)
|
December 4, 2025
Hexatic phase in covalent two-dimensional silver iodide
Thuy An Bui, David Lamprecht, Jacob Madsen, et al.
Diagnostics (Basel, Switzerland)
|
April 23, 2022
First-in-Human Study of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET for Integrin α<sub>v</sub>β<sub>3</sub> Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability
Malene Martini Clausen, Esben Andreas Carlsen, Camilla Christensen, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
June 27, 2012
Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response
Vibe Gedsoe Frokjaer, David Erritzoe, Klaus Kähler Holst, et al.
Nuclear Medicine and Biology
|
November 21, 2012
Radiolabelling and PET brain imaging of the α₁-adrenoceptor antagonist Lu AE43936
Rune Risgaard, Anders Ettrup, Thomas Balle, et al.
Scientific Reports
|
October 31, 2024
Phase II study of uPAR-PET/CT for staging of primary breast cancer in comparison with ultrasound and fine needle biopsies
Marie Øbro Fosbøl, Esben Andreas Carlsen, Malene Brandt-Larsen, et al.
Page
of 11